Given the fact that strategies that reduce MDSC-mediated immunosuppression can enhance the efficacy of checkpoint blockade in various tumors, we investigated if treatment of ibrutinib can improve the anti-PDL1 therapy in NB. Here, CD274 is linked to neuroblastoma.